

1/2

SEQUENCE LISTING

```
<110> DUBOIS, Claire
    <120> USE OF FURIN AND FURIN-LIKE PROTEASE INHIBITORS IN THE TREATMENT
    OF INFLAMMATORY OR MATRIX REMODELLING DISEASES
    <130>
           85761-28
    <140> US 09/885,914
10
    <141>
           2001-06-22
    <150>
           US 60/213,995
    <151>
           2000-06-26
15
    <150>
           CA 2,312,109
    <151>
           2000-06-23
    <160>
           3
20
    <170> PatentIn version 3.0
    <210>
    <211>
    <212>
           PRT
25
    <213> Homo sapiens
    <220>
    <221>
           SITE
    <222>
           (1)..(4)
30
    <223>
           Reactive site of alphal-antitrypsin
    <400> 1
    Ala Ile Pro Met
35
    1
    <210>
           2
    <211>
           4
    <212> PRT
    <213> Artificial/Unknown
40
    <220>
    <221> MUTAGEN
    <222>
           (1)..(1)
    <223> Variant of reactive site of alpha1-antitrypsin in which Ala355
45
    (position 1) has been replaced with Arg
    <220>
    <221> MUTAGEN
    <222>
           (4)..(4)
```

<223> Variant of reactive site of alphal-antitrypsin in which Met358

(position 4) has been replaced with Arg

50

```
<400> 2
    Arg Ile Pro Arg
    1
    <210>
           3
    <211>
           4
    <212>
           PRT
    <213> Artificial/Unknown
    <220>
10
    <221> MOD RES
    <222>
           (1)..(1)
           Arg at position 1 is modified at its amino group with a decanoyl
    <223>
    group
15
    <220>
    <221> MOD_RES
    <222>
           (4)..(4)
    <223> Arg at position 4 is modified at its carboxyl group with a -CH_2Cl
    group
20
    <400> 3
    Arg Val Lys Arg
    1
```